Invention Grant
- Patent Title: Expression of isoform 202 of ERCC1 for predicting response to cancer chemotherapy
-
Application No.: US14186285Application Date: 2014-02-21
-
Publication No.: US09702875B2Publication Date: 2017-07-11
- Inventor: Ken Olaussen , Jean-Charles Soria , Luc Friboulet
- Applicant: Ken Olaussen , Jean-Charles Soria , Luc Friboulet
- Applicant Address: FR Villejuif
- Assignee: INSTITUTE GUSTAVE-ROUSSY
- Current Assignee: INSTITUTE GUSTAVE-ROUSSY
- Current Assignee Address: FR Villejuif
- Agency: Trego, Hines & Ladenheim, PLLC
- Agent Brandon Trego; Jonathan Hines
- Priority: EP06290407 20060314
- Main IPC: G01N33/573
- IPC: G01N33/573 ; C12Q1/68 ; G01N33/574
Abstract:
An in vitro method for detecting the susceptibility of a tumor cell to a chemotherapy is disclosed. The method includes the step of measuring the expression level of the isoform 202 of the ERCC1 protein.
Public/Granted literature
- US20140170659A1 EXPRESSION OF ISOFORM 202 OF ERCC1 FOR PREDICTING RESPONSE TO CANCER CHEMOTHERAPY Public/Granted day:2014-06-19
Information query
IPC分类:
